Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carci… Read more
Market Cap & Net Worth: Biofrontera AG (B8FK)
Biofrontera AG (XETRA:B8FK) has a market capitalization of $16.78 Million (€16.35 Million) as of March 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #32203 globally and #3589 in its home market, demonstrating a 3.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofrontera AG's stock price €2.69 by its total outstanding shares 6076862 (6.08 Million).
Biofrontera AG Market Cap History: 2025 to 2026
Biofrontera AG's market capitalization history from 2025 to 2026. Data shows growth from $15.22 Million to $16.78 Million (0.00% CAGR).
Biofrontera AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofrontera AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of B8FK by Market Capitalization
Companies near Biofrontera AG in the global market cap rankings as of March 19, 2026.
Key companies related to Biofrontera AG by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Biofrontera AG Historical Marketcap From 2025 to 2026
Between 2025 and today, Biofrontera AG's market cap moved from $15.22 Million to $ 16.78 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €16.78 Million | +10.25% |
| 2025 | €15.22 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biofrontera AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.78 Million USD |
| MoneyControl | $16.78 Million USD |
| MarketWatch | $16.78 Million USD |
| marketcap.company | $16.78 Million USD |
| Reuters | $16.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.